The invention discloses a standard product for detecting genes of clinical medications for lung cancer and an application thereof, wherein the standard product comprises a lowest-detection-limit reference product at least comprising two different levels of variation-frequency DNA mixtures; and each level of variation-frequency DNA mixture comprises the following mutation sites: EGFR gene G719S, E746_A750del, S768I, T790M and L858R mutation sites, EML4-ALK gene E6, E20 and E13, E20 mutation site, SLC34A2-ROS1 gene E4, and E32 mutation site. By application of the technical scheme disclosed by the invention, whether a kit can detect the gene mutation and the gene frequency can be judged according to results, the accuracy of detection results of the existing kit can be verified and more accurate guidance also can be provided for clinical medications.